Marga B.V v Dermalogica South Africa (Pty) Ltd (LM022May23) [2023] ZACT 69 (7 September 2023)
- Citation
- [2023] ZACT 69
- Status
- Order
- Jurisdiction
- South Africa
- Court
- Competition Tribunal
- Panel
- S Goga, A Ndoni, F Tregenna
- Case number
- LM022May23
More details
- Court
- Competition Tribunal
- Panel
- S Goga, A Ndoni, F Tregenna
- Case number
- LM022May23
On this page
Professional case brief
Research organized from the available case record
01
Holding and result
The Tribunal found that the proposed merger between Marga B.V and Dermalogica South Africa (Pty) Ltd does not substantially prevent or lessen competition in any relevant market. However, the Tribunal determined that public interest considerations warranted the imposition of conditions. These conditions include commitments to education and training for HDP women and youth, supplier development for SMMEs, and the establishment of the Dermalogica Entrepreneurial Ownership Programme. The Tribunal further imposed monitoring and reporting obligations to ensure compliance. The merger was approved subject to these conditions, with the Tribunal retaining the authority to revoke approval in the event of non-compliance or deceit.
Court disposition
Merger approved subject to public interest conditions and compliance monitoring.
Orders
- The merger between Marga B.V and Dermalogica South Africa (Pty) Ltd is approved in terms of section 16(2)(b) of the Competition Act.
- A Merger Clearance Certificate is to be issued in terms of Competition Tribunal Rule 35(5)(a).
- The approval is subject to the conditions set out in Annexure A, including education and training, entrepreneurial ownership programme, supplier development, and compliance monitoring.
- The Tribunal may revoke approval if it was granted on the basis of incorrect information or obtained by deceit, or if any condition is breached.
02
Material facts
Parties
Marga B.V
ApplicantDermalogica South Africa (Pty) Ltd
Respondent03
Procedural history
Posture
Merger Application / Final Determination
04
Questions and positions
Legal issues
- 01
Whether the proposed merger between Marga B.V and Dermalogica South Africa (Pty) Ltd should be approved under section 16(2)(b) of the Competition Act.
- 02
Whether the merger should be subject to public interest conditions relating to historically disadvantaged persons (HDPs), youth, and SMMEs.
- 03
Whether the proposed education, training, entrepreneurial, and supplier development commitments are sufficient to address competition and public interest concerns.
Party arguments
- Applicant
- The applicant submitted that the merger would not substantially prevent or lessen competition in any relevant market. It argued that the transaction would result in positive public interest outcomes, including increased education and training opportunities for HDP women and youth, supplier development for SMMEs, and the establishment of the Dermalogica Entrepreneurial Ownership Programme. The applicant committed to compliance monitoring and reporting as required by the Tribunal.
- Respondent
- The respondent did not oppose the merger and confirmed its willingness to implement the proposed public interest conditions. It undertook to provide education and training, supplier development, and to establish the Dermalogica Entrepreneurial Ownership Programme for HDP women and youth. The respondent agreed to comply with all monitoring and reporting obligations imposed by the Tribunal.
05
Court’s reasoning
Legal principles
- 01
Competition Act No. 89 of 1998, sections 12A, 14A, and 16
A merger may be approved subject to conditions that promote public interest objectives, including empowerment of historically disadvantaged persons and support for SMMEs.
- 02
Competition Act No. 89 of 1998, section 16(3)
The Tribunal may impose conditions to ensure compliance with commitments made by the merger parties and may revoke approval if conditions are breached or approval was obtained by deceit.
- 03
Competition Tribunal Rules 35(5)(a), 37, and 39
Monitoring and reporting obligations are enforceable to ensure that merger parties comply with public interest conditions.
06
Ratio, limits and disposition
Ratio decidendi
The Tribunal found that the proposed merger between Marga B.V and Dermalogica South Africa (Pty) Ltd does not substantially prevent or lessen competition in any relevant market. However, the Tribunal determined that public interest considerations warranted the imposition of conditions. These conditions include commitments to education and training for HDP women and youth, supplier development for SMMEs, and the establishment of the Dermalogica Entrepreneurial Ownership Programme. The Tribunal further imposed monitoring and reporting obligations to ensure compliance. The merger was approved subject to these conditions, with the Tribunal retaining the authority to revoke approval in the event of non-compliance or deceit.
Obiter and limits
- The Tribunal emphasised the importance of ongoing monitoring and reporting to ensure that public interest conditions are effectively implemented.
- The Tribunal noted that the empowerment of HDP women and youth through education, training, and entrepreneurial support aligns with the objectives of the Competition Act.
- The Tribunal stated that supplier development for SMMEs is a key consideration in promoting inclusive economic growth.
Court disposition
Merger approved subject to public interest conditions and compliance monitoring.
- The merger between Marga B.V and Dermalogica South Africa (Pty) Ltd is approved in terms of section 16(2)(b) of the Competition Act.
- A Merger Clearance Certificate is to be issued in terms of Competition Tribunal Rule 35(5)(a).
- The approval is subject to the conditions set out in Annexure A, including education and training, entrepreneurial ownership programme, supplier development, and compliance monitoring.
- The Tribunal may revoke approval if it was granted on the basis of incorrect information or obtained by deceit, or if any condition is breached.
Source and reliance status
Competition Tribunal
This page organises the available record for research. Confirm quotations, current status, and subsequent treatment against the official source before relying on the case.
Judgment reading view
Judgment text
The complete available source text.
Competition Tribunal
Order
COMPETITION TRIBUNAL OF
SOUTH AFRICA
Case No: LM022May23
In the matter between:
Marga B.V Primary
Acquiring Firm
and
Dermalogica South Africa (Pty) Ltd Primary
Target Firm
Panel : S Goga (Presiding Member)
: A Ndoni (Tribunal Member)
: F Tregenna (Tribunal Member)
Heard on : 07
September 2023
Order issued on : 07 September 2023
ORDER
Further to the recommendation of the Competition Commission in terms of section 14A(1)(b) of the Competition Act, 1998 (“the Act”) the Competition Tribunal orders that–
1. the merger between the abovementioned parties be approved in terms of section 16(2)(b) of the Act; and
2. a Merger Clearance Certificate be issued in terms of Competition Tribunal Rule 35(5)(a).
Presiding Member Ms Sha’ista Goga
Concurring: Ms Andiswa Ndoni and Prof. Fiona Tregenna
Date: 07 September 2023
Merger Clearance Certificate
You applied to the Competition Commission on 17 May 2023 for merger approval in accordance with Chapter 3 of the Competition Act.
After reviewing all relevant information, and the recommendation or decision of the Competition Commission, the Competition Tribunal
approves the merger in terms of section 16(2) of the Act, for the reasons set out in the Reasons for Decision.
This approval is subject to: no conditions the conditions listed on the attached sheet
The Competition Tribunal has the authority in terms of section 16(3) of the Competition Act to revoke this approval if
a) it was granted on the basis of incorrect information for which a party to the merger was responsible.
b) the approval was obtained by deceit a firm concerned has breached an obligation attached to this approval.
The Registrar, Competition Tribunal
This form is prescribed by the Minister of Trade and Industry in terms of section 27 (2) of the Competition Act 1998 (Act No. 89 of 1998).
ANNEXURE A MARGA B.V.
DERMALOGICA
SOUTH AFRICA PROPRIETARY LIMITED
CASE NUMBER: LM022May23
CONDITIONS
1.
DEFINITIONS
1.1 The following expressions shall bear the meanings assigned to them below and cognate expressions bear corresponding meanings –
1.1.1 “Act” means the Competition Act No. 89 of 1998, as amended;
1.1.2 “Acquiring Firm” means Marga;
1.1.3 “Approval Date” means the date referred to on the Tribunal’s Merger Clearance Certificate;
1.1.4 “CAVI” means CAVI Brands Proprietary Limited;
1.1.5 "Conditions" means, collectively, the conditions referred to in this document;
1.1.6 “Days” means business days, being any day other than a Saturday, Sunday, or official public holiday in the Republic of South Africa;
1.1.7 “Dermalogica Entrepreneurial Ownership Programme” means a programme to be set up by Dermalogica SA which will be aimed at providing assistance to HDP women and Youth in growing their existing or setting up and owning their own standalone beauty salons. This will be achieved by providing such HDP women and Youth with assistance
such as, business training, access to entities who are able to provide start- up capital at preferential interest rates, consignment
stock and/or preferential payment terms on product purchases;
1.1.8 “Dermalogica Products” means the skincare products sold by Dermalogica SA in South Africa;
1.1.9 “Dermalogica SA” means Dermalogica South Africa Proprietary Limited;
1.1.10 “DISA” means the Dermal Institute of South Africa Proprietary Limited;
1.1.11 “HDPs” means historically disadvantaged persons within the meaning of the Act;
1.1.12 “Implementation Date” means the date, occurring after the Approval Date, on which the Merger is implemented by the Merger Parties;
1.1.13 “Marga” means Marga B.V;
1.1.14 “Marketing and Design Services” means any and all activities undertaken in relation to the promotion and sale of Dermalogica Products and the promotion of the Dermalogica brand;
1.1.15 “Merger” means the acquisition of joint control by Marga of Dermalogica SA notified under case no. 2023May0037 and LM022May23;
1.1.16 “Merger Parties” means Marga and CAVI;
1.1.17 "SMME" means small businesses and medium-sized businesses as described in the Act;
1.1.18 “Target Firm” means Dermalogica South Africa Proprietary Limited;
1.1.19 “Tribunal” means the Competition Tribunal of South Africa; and
1.1.20 “Youth” means HDPs between the ages of 18 and 34.
2
CONDITIONS
2.1
EDUCATION AND TRAINING
2.1.1. The Target Firm shall for a period of years following the Implementation Date provide education programs and training to tertiary students and qualified skincare therapists to the value of no less thanper annum. At least 60% of the spend on education and training should be towards HDP women and the Youth.
2.1.2. The education and training initiatives include, but is not limited, to the following:
2.1.2.1. In person classroom training at specialist DISA training centers in Durban, Johannesburg and Cape Town;
2.1.2.2. On-site practical training at DISA’s fully equipped skin centers;
2.1.2.3. Online training that offers students training in real time;
2.1.2.4. On-site training at salons for students and therapists to gain practical experience;
2.1.2.5. On-demand training which is pre-recorded and made available via a secure portal; and
2.1.2.6. Dermalogica Product training modules at South African Technicon’s and private beauty colleges.
3.
DERMALOGICA ENTREPRENEURIAL OWNERSHIP PROGRAMME (“DEOP”)
3.1. Dermalogica SA shall, within [….] months of the Implementation Date, implement the DEOP. Dermalogica SA shall, at its sole discretion, determine the identity of the DEOP participants that will participate in the DEOP. Dermalogica SA shall allocate a minimum of to the DEOP and this amount shall be utilised entirely for the purpose of the DEOP. For the avoidance of doubt, Dermalogica SA shall bear any other costs involved in setting up, managing and operating the DEOP.
3.2. The duration of the DEOP shall be at least [….] years.
3.3. Prior to the implementation of the DEOP, Dermalogica SA shall provide the Commission with details of the DEOP in writing. These details will include, but not be limited to, the structure of the DEOP, the terms of the DEOP, the identities of the DEOP participants and evidence that these participants are HDPs. The DEOP may not be implemented without the Commission’s approval.
4.
SUPPLIER DEVELOPMENT
4.1. The Target Firm shall for a period of [….] years following the Implementation Date spend no less than [….] per annum on Marketing and Design Services procured from SMMEs and HDP owned or controlled businesses.
4.2. At least 60% of the Marketing and Design Services will be procured from SMMEs and HDP owned or controlled businesses which are owned and controlled by HDP women and the Youth.
5.
MONITORING OF COMPLIANCE WITH CONDITIONS
5.1. The Acquiring Firm shall notify the Commission in writing of the Implementation Date, within 5 Days of the Implementation Date.
5.2. The Target Firm shall within 12 months of the Approval Date notify and provide the Commission with the details of the DEOP in writing. These details shall include the terms of the DEOP, the benefits of the DEOP, the identity of the beneficiaries and evidence that the beneficiaries are HDP women and Youth.
5.3. The Commission shall provide its approval of the DEOP within 30 Days of receipt of the notification referred to in clause 5.2 above.
5.4. The Target Firm shall within 40 Days of each anniversary of the Implementation Date provide a suitable and appropriately detailed annual report to the Commission regarding the Target Firm’s compliance with the Conditions, including the progress made in achieving each of the targets set out in these Conditions during the relevant reporting period.
5.5. The report referred to in clause 5.4 above, shall be accompanied by an affidavit attested to by a senior official of the Target Firm attesting to the accuracy of the annual report and full compliance of the Conditions in the 12-month period to which report relates.
5.6. The Commission may request additional information from the Merger Parties, which the Commission may, from time to time, deem necessary for purposes of monitoring the extent of compliance with these Conditions.
6.
APPARENT BREACH
Should the Commission receive any complaint in relation to non-compliance with the above Conditions, or otherwise determine that there has been an apparent breach of the Conditions, the breach shall be dealt with in terms of Rule 37 of the Rule for the Conduct of Proceedings in the Tribunal read together with Rule 39 of the Rules for the Conduct of Proceedings in the Commission.
7.
VARIATION
The Commission and/or Merger Parties may at any time, on good cause shown, apply to the Tribunal for the Conditions or any part thereof to be waived, relaxed, modified and /or substituted.
8.
GENERAL
All correspondence in relation these Conditions must be submitted to the following email addresses: mergerconditions@compcom.co.za.
Case-aware research
Ask AI about this case
The judgment and available research above are public. New questions open in a separate private conversation grounded in this case.